Therapeutic effects of entecavir combined with adefovir dipivoxil on lamivudine-resistant chronic hepatitis B
Abstract：Objective To investigate the therapeutic effects of entecavir (ETV) combined with adefovir dipivoxil (ADV) on lamivudine (LAM)-resistant chronic hepatitis B (CHB).Methods A total of 160 patients with LAM resistant CHB who were diagnosed and treated in our hospital from January 2011 to January 2013 were randomly divided ETV+ADV treatment group (group A,n=80) and LAM+ADV treatment group (group B,n=80).The patients in group A were treated by ETV (0.5mg/d) and ADV (10mg/d),however,the patients in group B were treated by LAM (100mg/d) and ADV (10mg/d). At 12w,24w,48w,96w after treatment, the levels of HBV-DNA,HBeAg,HBsAg,alanine aminotransferase (ALT),renal function,routine blood test and B-ultrasound were observed and compared between two groups.Results The proportion of the patients(HBV-DNA<500IU/ml) at 12w,24w,48w,96w after treatment in group A was 55%,75%,80%, 85%,respectively,which was 26.25%,42.5%,45%,60%,respectively in group B (P <0.01).However there were no significant differences in HBeAg clearance rate and seroconversion rate between the two groups (P>0.05).In addition the ALT normal rate was 65%,80%,90%,95%,respectively in group A,however,which was 37.5%,57.5%,62.5%,80%, respectively in group B (P <0.05). Besides there was significant difference in the thickness of spleen at 48w,96w after treatment between two groups (P<0.05).Finally no abnormally increase of serum creatinine (Scr) and decrease of serum inorganic phosphorus during treatment were observed in both groups. Conclusion The combination treatment of ETV combined with ADV can achieve satisfactory therapeutic effects on LAM-resistant CHB,with better safety.
Keywords：entecaviradefovirlamivudinecombination therapyresistance
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 990-993,998 )